Special Authority forms by condition

Last updated on July 30, 2024

Special Authority eForms are easier to submit and return decisions quicker than faxing paper forms.

Special Authority requests must be completed by a licensed medical prescriber.

Patients can find find out if Special Authority requests have been approved at Health Gateway. Prescribers can call the toll-free Medical Practitioner Line at 1-866-905-4912. Do not send a request by fax.

If you can't find the form you need below, search the Special Authority drugs list

Jump to: CGM/FGM, insulin pumps and blood glucose test strips | Compounded medications

Expand All | Collapse All

General Special Authority request (use only if there is no specific form below)

eForms are simpler and quicker than faxing. Enrol now.

5328	Log in to eForms General Special Authority Request (PDF, 656KB)

Atopic dermatitis

abrocitinib, upadacitinib

5852	Log in to eForms Abrocitinib and upadacitinib for atopic dermatitis (PDF, 721 KB)

Alzheimer's disease

donepezil, galantamine, rivastigmine

5465	Log in to eForms Donepezil, galantamine and rivastigmine (PDF, 350KB)
—	Standardized Mini-Mental State Examination (SMMSE) (PDF, 690KB)
—	Global Deterioration Scale (GDS) (PDF, 198KB)

Antiviral

letermovir

5816	Log in to eForms Letermovir Special Authority Request Form (PDF, 358KB)

Arthritis: ankylosing spondylitis

adalimumab, etanercept, golimumab, infliximab, secukinumab

5364	BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) (PDF, 64KB)
5365	Log in to eForms Adalimumab/Etanercept/Golimumab/Infliximab/secukinumab for Ankylosing Spondylitis: Initial/Switch (PDF, 242KB)
5366	Log in to eForms Adalimumab/Etanercept/Golimumab/Infliximab/secukinumab for Ankylosing Spondylitis: Renewal (PDF, 237KB)

Arthritis: psoriatic

adalimumab, etanercept, golimumab, infliximab, secukinumab

5360	Adalimumab/Etanercept/Golimumab/Infliximab/secukinumab for Psoriatic Arthritis: Initial/Switch (PDF, 241KB)
5361	Adalimumab/Etanercept/Golimumab/Infliximab/secukinumab for Psoriatic Arthritis: Renewal (PDF, 224KB)
5364	BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) (PDF, 64KB)
5383	Patient Health Assessment Questionnaire (HAQ) (PDF, 528KB)

Arthritis: rheumatoid

For cyclosporine and leflunomide, please use the General Special Authority Request (PDF, 656KB).

abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab

5345	Abatacept/Adalimumab/Certolizumab/Etanercept/Golimumab/Infliximab/Tocilizumab for Rheumatoid Arthritis: Initial/Switch (PDF, 604KB)
5354	Abatacept/Adalimumab/Certolizumab/Etanercept/Golimumab/Infliximab/Tocilizumab for Rheumatoid Arthritis: Renewal (PDF, 406KB)
5373	Rituximab for Rheumatoid Arthritis: Initial/Renewal (PDF, 388KB)
5383	Patient Health Assessment Questionnaire (HAQ) (PDF, 528KB)

Attention deficit hyperactivity disorder (ADHD)

mixed-amphetamine salts ER, lisdexamfetamine, methylphenidate ER (Concerta-type generics), atomoxetine

5472	Medication Coverage for Attention Deficit and Hyperactivity Disorder (PDF, 606KB)

Blood disorders

deferasirox, iron isomaltoside, iron sucrose, luspatercept

5407	Deferasirox coverage: Initial/Switch (PDF, 360KB)
5818	Intravenous iron for iron deficiency anemia (PDF, 90KB)
5827	Luspatercept for anemia associated with beta-thalassemia (PDF, 130KB)

Cancer treatment supportive care

filgrastim

5470	Filgrastim (Grastofil Type) (PDF, 544KB)

Cardiovascular conditions

dabigatran, ticagrelor, ivabradine, sacubitril-valsartan, ARBs (candesartan, eprosartan, icosapent ethyl, irbesartan, losartan, olmesartan, telmisartan, valsartan)

5825	Icosapent ethyl for cardiovascular diseass (PDF, 344KB)
5391	Dabigatran for atrial fibrillation (PDF, 507KB)
5395	Ticagrelor for acute coronary syndromes (PDF, 460KB)
5484	Sacubitril-valsartan for heart failure (PDF, 382KB)
5488	Ivabradine for heart failure (PDF, 302KB)
5492	ARBs: candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan (PDF, 672KB)

Diabetes

empagliflozin, empagliflozin-metformin, insulin detemir, insulin glargine, linagliptin, pioglitazone, saxagliptin, semaglutide

For diabetes-related supplies, visit glucose monitors, insulin pumps, blood glucose test strips

5396	Insulin glargine and insulin detemir (PDF, 500KB)
5826	Empagliflozin, semaglutide: Second-line anti-diabetic medications (PDF 747KB)
5481	Linagliptin, saxagliptin, pioglitazone: Third-Line Anti-Diabetic Medications (PDF, 633KB)

Gastrointestinal disorders

proton pump inhibitors, adalimumab, infliximab, rifaximin, vedolizumab, obeticholic acid

5350	Proton pump inhibitors (PDF, 472KB)
5368	Biologics for moderate to severe active Crohn’s/fistulizing Crohn’s: Initial/Switch (PDF, 751KB)
5495	Biologics for moderate to severe active Crohn’s/fistulizing Crohn’s: Renewal (PDF, 607KB)
5374	Worksheet (based on Harvey-Bradshaw Index) (PDF, 514KB)
5388	Biologics for ulcerative colitis: Initial/Switch (PDF, 940KB)
5497	Biologics for ulcerative colitis: Renewal (PDF, 608KB)
5483	Rifaximin (PDF, 299KB)
5490	Obeticholic acid for primary biliary cholangitis (PDF, 315KB)

General autoimmune conditions

rituximab

5848	Rituximab for autoimmune conditions (PDF, 725KB)

Graft vs. host disease

Ruxolitinib

5850	Ruxolitinib for Graft vs host disease (PDF, 220KB)

Hepatitis

Hepatitis B: adefovir, entecavir, interferon alpha, lamivudine, tenofovir
Hepatitis C: asunaprevir, daclatasvir, ledipasvir-sofosbuvir, pegylated interferon plus ribavirin, simeprevir, sofosbuvir, velpatasvir-sofosbuvir, sofosbuvir-velpatasvir-voxilaprevir, glecaprevir-pibrentasvir

5372	Chronic Hepatitis B: Initial/Renewal (PDF, 189KB)
5473	Sofosbuvir in Combination with Ribavirin for Chronic Hepatitis C (PDF, 413KB)
5476	Velpatasvir Plus Sofosbuvir With/Without Ribavirin for Chronic Hepatitis C (PDF, 413KB)
5478	Ledipasvir Plus Sofosbuvir With/Without Ribavirin for Chronic Hepatitis C (PDF, 419KB)
5486	Sofosbuvir-velpatasvir-voxilaprevir for Chronic Hepatitis C (PDF, 414KB)
5494	Glecaprevir plus pibrentasvir (PDF, 663KB)

Hypercholesterolemia

evolocumab

5493	Evolocumab for heterozygous familial hypercholesterolemia (PDF, 586KB)

Inflammatory conditions

tocilizumab

5496	Tocilizumab for giant cell arteritis (PDF, 316KB)

Kidney disease

finerenone

5856	finerenone for end-stage kidney disease

Metabolic conditions

sapropterin

5815	sapropterin form (PDF, 734KB)

Migraine

fremanezumab, galcanezumab, eptinezumab

5822	CGRP Antagonists for Migraine Prevention (PDF, 1.02MB)

Multiple sclerosis

alemtuzurnab, cladribine, dimethyl fumarate, fingolimod, glatiramer, interferon beta, natalizumab, ocrelizumab, rituximab, siponimod, teriflunomide

5351	Disease Modifying Drugs for Multiple Sclerosis: Initial/Renewal/Switch (PDF, 785KB)
5385	Natalizumab (Tysabri) for Multiple Sclerosis: Initial/Renewal (PDF, 568KB)
5394	Fingolimod for Multiple Sclerosis: Initial/Renewal (PDF, 323KB)
5482	Alemtuzumab (Lemtrada) for Multiple Sclerosis (PDF, 519KB)
5813	Ocrelizumab for Primary Progressive Multiple Sclerosis (PDF, 594KB)
5820	Cladribine (Mavenclad) for Multiple Sclerosis (PDF, 919KB)
5821	Siponimod (Mayzent) for Secondary Multiple Sclerosis (PDF, 1MB)

Neurodegenerative conditions

Amifampridine (gov.bc.ca) for Lambert-Eaton Myasthenic Syndrome – I think it goes under neurodegenerative conditions

amifampridine, edaravone

5828	Amifampridine for Lambert-Eaton myasthenic syndrome
5814	Edaravone for Amyotrophic Lateral Sclerosis (ALS) (PDF, 93KB)

Neuromyelitis optica spectrum disorder (NMOSD)

rituximab, tocilizumab

5812	Satralizumab for neuromyelitis optica spectrum disorder (NMOSD)
5851	Rituximab / Tocilizumab for neuromyelitis optica spectrum disorder (PDF, 710KB)

Parkinson's disease

levodopa-carbidopa

5810	Duodopa (PDF, 599KB)

Respiratory conditions

aclidinium, aclidinium/formoterol, glycopyrronium, glycopyrronium/indacaterol, indacaterol, nintedanib, salmeterol, salmeterol/ fluticasone, tiotropium 18 mcg, tiotropium/olodaterol, umeclidinium/vilanterol, umeclidinium/vilanterol/ fluticasone, vilanterol/fluticasone, benralizumab, mepolizumab, nintedanib, pirfenidone

Nintedanib for Progressive Pulmonary Fibrosis

5823	Nintedanib for progressive pulmonary fibrosis (PDF, 398KB)
5362	Inhalers for chronic obstructive pulmonary disease (COPD) (PDF, 403KB)
5468	Nintedanib and pirfenidone for idiopathic pulmonary fibrosis (PDF, 532KB)
5489	Benralizumab and Mepolizumab for severe eosinophilic asthma (PDF, 431 KB)
5824	Asthma triple inhaler (ICS-LABA-LAMA) (PDF, 1.08MB)

Skin disorders

adalimumab, etanercept, infliximab, secukinumab, ustekinumab, ixekizumab

5379	Psoriasis Area and Severity Index (PASI) Worksheet (PDF, 529KB)
5380	Biologics for moderate to severe psoriasis (PDF, 365KB)
5485	Adalimumab for the treatment of active moderate to severe hidradenitis suppurativa (PDF, 310KB)

Vasculitis

rituximab

5393	Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: Initial/Renewal (PDF, 500KB)

Venous thromboembolic disease

dalteparin, enoxaparin, nadroparin, tinzaparin

5338	Dalteparin/Enoxaparin (Biosimilar)/Nadroparin/Tinzaparin Low Molecular Weight Heparin (PDF, 548KB)
5469	Dalteparin/Tinzaparin/Enoxaparin (Biosimilar) for Treatment of Venous Thromboembolism in Cancer Patients (PDF, 573KB)

Glucose monitors, insulin pumps, blood glucose test strips

Expand All | Collapse All

Glucose monitoring systems

5817	Dexcom G6, G7, and FreeStyle Libre 2 (PDF, 92KB)

Insulin pumps

5375	Continuous subcutaneous insulin infusion (insulin pump): Initial/Renewal (PDF, 473KB)

Additional blood glucose test strips

5398	Additional blood glucose test strips (PDF, 301KB)

Compounded medications

5479	Compound Coverage Request (PDF, 536KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.